This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Article abstract-Docetaxel (Taxotere), a semisynthetic analogue of the antitumor agent paclitaxel, inhibits tubulin depolymerization. Paclitaxel produces a peripheral neuropathy. This study delineates clinically and electrophysiologically the characteristics of a peripheral neuropathy due to docetaxel. In 186 patients receiving docetaxel in phase I or phase II protocols, we performed serial neurologic exams. As patients became symptomatic, quantitative sensory testing and nerve conduction studies were done. Twenty-one patients developed mild to moderate sensory neuropathy on taxotere at a wide range of cumulative doses (50 to 750 mg/m2) and dose levels (10 to 115 mg/m2). Ten of these patients also developed weakness of varying degree in proximal and distal extremities. Nine of the 21 patients had received neurotoxic chemotherapy before; 16 were treated with docetaxel at a dose level of 100 to 115 mg/m2. In summary, docetaxel produced a sensorimotor peripheral neuropathy in 11% of our patient population.
NEUROLOGY 1996;46: 108-111
- Copyright 1996 by Advanstar Communications Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis
Prof. Massimo Filippi and Dr. Paolo Preziosa